• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性非 COVID-19 病毒性肺炎的组织学特征和临床病程。

Histologic Characteristics and Clinical Courses of Primary Viral Pneumonia Other than COVID-19.

机构信息

Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan.

Department of Pathology, Saitama Cardiovascular and Respiratory Center, Japan.

出版信息

Intern Med. 2023 Dec 15;62(24):3609-3617. doi: 10.2169/internalmedicine.2433-23. Epub 2023 Sep 29.

DOI:10.2169/internalmedicine.2433-23
PMID:37779065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10781553/
Abstract

Objective To clarify both the histologic changes in primary viral pneumonia other than COVID-19 and whether patients with severe lung injury (SLI) on biopsy specimens progress to severe respiratory insufficiency. Methods Patients with primary viral pneumonia other than COVID-19, who underwent lung tissue biopsy, were retrospectively studied. Patients Forty-three patients (41 living patients and 2 autopsied cases) were included in the study. Results Nine patients had SLI, whereas most of patients who recovered from primary viral pneumonia showed a nonspecific epithelial injury pattern. One patient underwent a biopsy under mechanical ventilation. Two of 8 (25.0%) patients on ambient air or low-flow oxygen therapy progressed to a severe respiratory condition and then to death, while only 1 (3.1%) of 32 patients without SLI progressed to a severe respiratory condition and death (p=0.096). The proportion of patients who required O treatment for ≥2 weeks was higher in patients with SLI than in those without SLI (p=0.033). The 2 autopsy cases showed a typical pattern of diffuse alveolar damage, with both showing hyaline membranes. Non-specific histologic findings were present in 32 patients without SLI. Conclusion Some patients with SLI progressed to severe respiratory insufficiency, whereas those without SLI rarely progressed to severe respiratory insufficiency or death. The frequency of patients progressing to a severe respiratory condition or death did not differ significantly between those with and without SLI. The proportion of patients who required longer O treatment was higher in SLI group than in those without SLI.

摘要

目的 阐明除 COVID-19 以外的原发性病毒性肺炎的组织学变化,以及活检标本中有严重肺损伤 (SLI) 的患者是否会进展为严重呼吸功能不全。

方法 对接受肺组织活检的除 COVID-19 以外的原发性病毒性肺炎患者进行回顾性研究。

结果 共纳入 43 例患者(41 例存活患者和 2 例尸检病例)。9 例患者有 SLI,而大多数从原发性病毒性肺炎中恢复的患者表现出非特异性上皮损伤模式。1 例患者在机械通气下行活检。8 例接受环境空气或低流量氧疗的患者中,有 2 例(25.0%)进展为严重呼吸状况,继而死亡,而 32 例无 SLI 的患者中仅 1 例(3.1%)进展为严重呼吸状况和死亡(p=0.096)。有 SLI 的患者需要接受 O 治疗≥2 周的比例高于无 SLI 的患者(p=0.033)。2 例尸检病例均表现为弥漫性肺泡损伤的典型模式,均有透明膜形成。32 例无 SLI 的患者表现出非特异性组织学发现。

结论 一些 SLI 患者进展为严重呼吸功能不全,而无 SLI 的患者很少进展为严重呼吸功能不全或死亡。有 SLI 和无 SLI 的患者进展为严重呼吸状况或死亡的频率无显著差异。需要接受 O 治疗较长时间的患者比例在 SLI 组高于无 SLI 组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/36ba7bdacce0/1349-7235-62-3609-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/90f1e6f71441/1349-7235-62-3609-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/1670fceb8523/1349-7235-62-3609-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/85b762aaa58f/1349-7235-62-3609-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/36ba7bdacce0/1349-7235-62-3609-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/90f1e6f71441/1349-7235-62-3609-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/1670fceb8523/1349-7235-62-3609-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/85b762aaa58f/1349-7235-62-3609-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd23/10781553/36ba7bdacce0/1349-7235-62-3609-g004.jpg

相似文献

1
Histologic Characteristics and Clinical Courses of Primary Viral Pneumonia Other than COVID-19.原发性非 COVID-19 病毒性肺炎的组织学特征和临床病程。
Intern Med. 2023 Dec 15;62(24):3609-3617. doi: 10.2169/internalmedicine.2433-23. Epub 2023 Sep 29.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
5
Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD.新型冠状病毒疾病 2019 感染导致的弥漫性肺泡损伤(DAD)在形态上与其他 DAD 病因无法区分。
Histopathology. 2020 Oct;77(4):570-578. doi: 10.1111/his.14180. Epub 2020 Sep 12.
6
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.沙利鲁单抗对比标准治疗用于住院 COVID-19 肺炎患者的早期治疗:SARTRE:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 16;21(1):794. doi: 10.1186/s13063-020-04633-3.
7
[Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].[新型冠状病毒肺炎患者呼吸支持的最新应用立场文件 - 德国呼吸学会]
Pneumologie. 2020 Jun;74(6):337-357. doi: 10.1055/a-1157-9976. Epub 2020 Apr 22.
8
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究:一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
9
Antemortem vs Postmortem Histopathologic and Ultrastructural Findings in Paired Transbronchial Biopsy Specimens and Lung Autopsy Samples From Three Patients With Confirmed SARS-CoV-2.生前与死后经支气管镜活检标本和尸检肺组织样本的组织病理学和超微结构观察:三例确诊 SARS-CoV-2 患者的对比研究。
Am J Clin Pathol. 2022 Jan 6;157(1):54-63. doi: 10.1093/ajcp/aqab087.
10
Outcomes Among Mechanically Ventilated Patients With Severe Pneumonia and Acute Hypoxemic Respiratory Failure From SARS-CoV-2 and Other Etiologies.严重肺炎和急性低氧性呼吸衰竭机械通气患者的结局:来自 SARS-CoV-2 和其他病因。
JAMA Netw Open. 2023 Jan 3;6(1):e2250401. doi: 10.1001/jamanetworkopen.2022.50401.

本文引用的文献

1
Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19.严重 COVID-19 中肺泡、内皮和器官损伤标志物的动态变化。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):507-519. doi: 10.1164/rccm.202106-1514OC.
2
Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients.机械通气 COVID-19 ICU 患者的血管内皮和上皮肺损伤标志物。
Crit Care. 2021 Feb 19;25(1):74. doi: 10.1186/s13054-021-03499-4.
3
Comparison of initial high-resolution computed tomography (HRCT) features of coronavirus disease 2019 (COVID-19) pneumonia and other viral pneumonias.
比较 2019 年冠状病毒病(COVID-19)肺炎和其他病毒性肺炎的初始高分辨率计算机断层扫描(HRCT)特征。
Ann Palliat Med. 2021 Jan;10(1):560-571. doi: 10.21037/apm-20-2479.
4
Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.新型冠状病毒病 2019 与严重急性呼吸综合征和 H1N1 流感的肺部组织病理学比较:系统综述。
Chest. 2021 Jan;159(1):73-84. doi: 10.1016/j.chest.2020.09.259. Epub 2020 Oct 7.
5
A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.对 COVID-19 病理学发现的系统回顾:疾病进展的病理生理学时间轴和可能机制。
Mod Pathol. 2020 Nov;33(11):2128-2138. doi: 10.1038/s41379-020-0603-3. Epub 2020 Jun 22.
6
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
7
Pulmonary pathology of early-phase COVID-19 pneumonia in a patient with a benign lung lesion.伴有良性肺病变的 COVID-19 肺炎早期患者的肺部病理学。
Histopathology. 2020 Nov;77(5):823-831. doi: 10.1111/his.14138. Epub 2020 Sep 15.
8
Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT.放射科医生在胸部 CT 鉴别 COVID-19 与非 COVID-19 病毒性肺炎中的表现。
Radiology. 2020 Aug;296(2):E46-E54. doi: 10.1148/radiol.2020200823. Epub 2020 Mar 10.
9
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.两例肺癌患者 2019 年新型冠状病毒(COVID-19)肺炎早期阶段的肺部病理学表现。
J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
10
Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases.需要与急性和进行性弥漫性间质性肺疾病相鉴别的病毒性肺炎
Intern Med. 2019;58(24):3509-3519. doi: 10.2169/internalmedicine.2696-19. Epub 2019 Dec 15.